The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | Validation of 2022 diagnostic & prognostic classifications of AML
Enrico Attardi, MD, University of Rome Tor Vergata, Rome, Italy, shares the findings of a real-world study investigating the applicability of the recently published diagnostic classifications of acute myeloid leukemia (AML) by the ICC and WHO, as well as the updated prognostic classification of AML by the European LeukemiaNet (ELN). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
